ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Sep 30
In fiscal 2025, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $829.45M, up 23258.2% from the prior year. The company was profitable, with a net margin of 3.6%.
Key ratios (FY2025)
11.9%
Operating margin
3.6%
Net margin
6.0%
Return on equity
+23258.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $829.45M | $3.55M | $240.74M | $243.23M | $138.29M | $87.99M | $168.80M | $16.14M | $31.41M | — |
| Operating Income | $98.35M | -$601.08M | -$205.00M | -$178.51M | -$149.04M | -$93.16M | $61.19M | -$55.94M | -$37.00M | -$81.74M |
| Net Income | $30.11M | -$609.69M | -$209.28M | -$176.49M | -$140.85M | -$84.55M | $67.97M | -$54.45M | -$34.38M | -$81.72M |
| EPS (Diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.72 | $-0.65 | $-0.47 | — |
| Total Assets | $1.39B | $1.14B | $765.55M | $691.94M | $710.15M | $522.50M | $349.85M | $111.61M | $104.02M | $128.18M |
| Shareholders' Equity | $503.42M | $191.06M | $287.16M | $418.34M | $408.82M | $461.78M | $244.04M | $95.24M | $80.87M | $95.02M |
| Cash & Equivalents | — | — | — | — | $184.43M | $143.58M | $221.80M | $30.13M | $24.84M | $85.37M |
| Operating Cash Flow | $179.55M | -$462.85M | -$153.89M | -$136.13M | $171.31M | -$95.80M | $173.03M | -$47.22M | -$23.94M | -$64.43M |
| Capital Expenditures | $22.67M | $141.47M | $176.74M | $52.78M | $23.57M | $11.95M | $12.00M | $1.42M | $7.92M | $3.86M |
| Shares Outstanding | 135.70M | 124.38M | 107.31M | 105.96M | 104.33M | 102.38M | 95.51M | 88.51M | 74.79M | 69.75M |